Australian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced the expansion of its management team with the appointment of three executives in the US.
The company said the appointments will drive its antimicrobial and dermatology programs.
Dr Clarence Young joins Botanix as chief medical officer, Anthony Robinson as vice president of development and Lynda Berne as head of commercial.
“We are very pleased to welcome Clarence, Anthony and Lynda to the Botanix team at an exciting time when we are ramping up our clinical and commercial activities off the back of our recent successful BTX 1801 study,” said Vince Ippolito, Botanix president and executive chairman.
“The depth and breadth of clinical and drug development experience that each of these executives bring to Botanix is exceptional and well suited to our near-term needs as we kick-off the BTX 1702 rosacea study and finalise planning for our next BTX 1801 study.”
Dr Young was recently chief medical officer at Velicept Therapeutics and senior vice-president and chief Medical officer at Iroko Pharmaceuticals, where he provided clinical and medical leadership for three NDA filings and approvals. He also has held executive leadership positions for Novartis and GSK.
Anthony Robinson was recently vice president, head of clinical operations, program management and regulatory affairs at Advicenne. He previously held senior positions at Shire (Takeda) and Covance.
Lynda Berne is a founder of BAL Pharma Consulting and previously held senior roles at Bristol Myers Squibb, Abbott and Shire.
Botanix is progressing a pipeline that includes assets focussed on dermatology and antimicrobial.